Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In a study, increased expression of VEGFR2 was found after BPC-157 treatment in rats with hind limb ischemia that further activated the VEGFR2-Akt-eNOS pathway
Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection
Key supporting research from 2024-2025 includes a July 2024 paper in Inflammopharmacology (PMID: 38980576) linking BPC-157 to stress response mechanisms, a January 2025 HSS Journal systematic review on neuromuscular applications (PMID: 40756949), and a 2025 Journal of Neuropsychiatry and Clinical Neurosciences perspectives paper positioning BPC-157 as an emerging therapeutic for CNS disorders
Suspected adverse reactions should be reported through the MHRA Yellow Card scheme
US$ 23.86
US$ 21.74
US$ 20.57
US$ 27.97
US$ 21.56
US$ 27.21
